Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$1.01 +4.1%	$1.11	$0.85 ▼ $4.22	$32.49M	0.22	39,702 shs	38,654 shs
MCRB Seres Therapeutics	$16.69 -1.0%	$11.91	$6.53 ▼ $26.40	$146.11M	2.9	134,532 shs	55,391 shs
OKYO OKYO Pharma	$2.65 +0.4%	$2.70	$0.85 ▼ $3.35	$99.67M	-0.09	149,165 shs	710,371 shs
SPRO Spero Therapeutics	$1.91 -3.5%	$2.59	$0.51 ▼ $3.22	$107.49M	1.39	810,837 shs	1.05 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	0.00%	+2.01%	-10.63%	-20.48%	-68.93%
MCRB Seres Therapeutics	0.00%	+17.45%	+18.54%	+123.73%	-7.60%
OKYO OKYO Pharma	0.00%	-18.96%	-8.62%	+79.05%	+165.03%
SPRO Spero Therapeutics	0.00%	-12.79%	-22.98%	+193.39%	+56.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKTX Akari Therapeutics	3.1104 of 5 stars	3.5	3.0	0.0	3.3	3.3	0.0
MCRB Seres Therapeutics	3.364 of 5 stars	2.9	1.0	4.6	3.3	0.8	0.0
OKYO OKYO Pharma	3.1453 of 5 stars	3.5	5.0	0.0	3.1	1.7	0.0
SPRO Spero Therapeutics	4.0333 of 5 stars	3.3	3.0	4.7	3.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	3.00	Buy	$5.00	395.10% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	341.38% Upside
OKYO OKYO Pharma	3.00	Buy	$7.00	164.15% Upside
SPRO Spero Therapeutics	2.50	Moderate Buy	$5.00	161.78% Upside

Current Analyst Ratings Breakdown

Latest AKTX, MCRB, OKYO, and SPRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/18/2025	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$0.80 per share	N/A
MCRB Seres Therapeutics	$126.32M	1.16	N/A	N/A	$3.76 per share	4.44
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.16) per share	N/A
SPRO Spero Therapeutics	$47.98M	2.24	N/A	N/A	$0.58 per share	3.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$19.79M	N/A	0.00	∞	N/A	N/A	-78.03%	-31.62%	8/18/2025 (Estimated)
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-350.16%	-67.69%	N/A
OKYO OKYO Pharma	-$4.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	-$68.57M	-$0.98	N/A	N/A	N/A	-110.35%	-120.27%	-55.61%	N/A

Latest AKTX, MCRB, OKYO, and SPRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	SPRO Spero Therapeutics	-$0.38	-$0.03	+$0.35	-$0.03	$11.00 million	$14.19 million
8/6/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	-$2.27	+$0.45	-$2.27	$11.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.19	0.16
MCRB Seres Therapeutics	N/A	1.57	1.57
OKYO OKYO Pharma	N/A	0.40	0.40
SPRO Spero Therapeutics	N/A	3.97	2.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
MCRB Seres Therapeutics	59.34%
OKYO OKYO Pharma	2.97%
SPRO Spero Therapeutics	25.60%

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	38.10%
MCRB Seres Therapeutics	4.70%
OKYO OKYO Pharma	40.46%
SPRO Spero Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	9	32.18 million	19.92 million	Not Optionable
MCRB Seres Therapeutics	330	8.75 million	8.34 million	Optionable
OKYO OKYO Pharma	7	37.61 million	22.39 million	Not Optionable
SPRO Spero Therapeutics	150	56.28 million	53.18 million	Optionable

AKTX, MCRB, OKYO, and SPRO Headlines

Recent News About These Companies

Spero Therapeutics (NASDAQ:SPRO) Releases Earnings Results, Beats Expectations By $0.32 EPS

August 14 at 4:36 PM | marketbeat.com

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2025 Earnings Call Transcript

August 13, 2025 | insidermonkey.com

Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

August 13, 2025 | finanznachrichten.de

Spero Therapeutics Reports Q2 2025 Results and Trial Success

August 13, 2025 | msn.com

Spero Therapeutics Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

August 12, 2025 | globenewswire.com

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

August 5, 2025 | globenewswire.com

Spero Therapeutics (SPRO) Expected to Announce Quarterly Earnings on Monday

July 28, 2025 | marketbeat.com

While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership

June 28, 2025 | finance.yahoo.com

Spero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

June 11, 2025 | seekingalpha.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | msn.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | insidermonkey.com

GSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMC

May 30, 2025 | pharmabiz.comP

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr

May 29, 2025 | thepharmaletter.comT

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone

May 29, 2025 | msn.com

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

May 29, 2025 | zacks.com

GSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soars

May 28, 2025 | endpts.comE

GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win

May 28, 2025 | fiercebiotech.comF

Spero Therapeutics Shares Soar as Trial with GSK Ends Early on Efficacy

May 28, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX, MCRB, OKYO, and SPRO Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$1.01 +0.04 (+4.10%)

Closing price 08/15/2025 03:54 PM Eastern

Extended Trading

$1.00 -0.01 (-1.08%)

As of 08/15/2025 04:10 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Seres Therapeutics NASDAQ:MCRB

$16.69 -0.17 (-1.01%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$16.28 -0.41 (-2.46%)

As of 08/15/2025 07:58 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

OKYO Pharma NASDAQ:OKYO

$2.65 +0.01 (+0.38%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.64 -0.01 (-0.23%)

As of 08/15/2025 07:59 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Spero Therapeutics NASDAQ:SPRO

$1.91 -0.07 (-3.54%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.96 +0.05 (+2.36%)

As of 08/15/2025 07:41 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time